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Lymphomatoid Papulosis Type B in a Patient with 
Crohn’s Disease Treated with TNF-Alpha Inhibitors  
Infliximab and Adalimumab
Dear Editor,
Lymphomatoid papulosis (LP) is a chronic, recur-
rent, usually self-limited papulonecrotic or papulo-
nodular skin disease, which belongs to the group of 
primary cutaneous CD30+ lymphoproliferative disor-
ders (1). Three main histological subtypes of LP have 
been recognized: type A (histiocytic), type B (myco-
sis fungoides-like), and type C (anaplastic large cell 
lymphoma-like). Recently, new histologic LP variants 
classified as type D (CD8-positive, cytotoxic form) and 
type E (angioinvasive form) have also been described. 
The etiology of LP has not been determined to date 
(2-4). Herein we report a case of LP type B evolving 
in a patient with Crohn’s disease after treatment with 
infliximab and adalimumab. 
A 38-year-old man suffering from terminal ileitis 
form of luminar Crohn’s disease for 10 years present-
ed at our department. During the last 10 years, the 
patient had been treated with a number of conven-
tional disease-modifying anti-inflammatory drugs 
including non-steroid anti-inflammatory drugs, me-
salazine, and immunomodulatory agents such as cor-
ticosteroids and azathioprine. As the disease was not 
sufficiently controlled, TNF-α inhibitor therapy was 
initiated. Infliximab was administered in standard 
dosage (5 mg/kg body weight every 8 weeks after 
the induction period) for one year. Concomitant ther-
apy with azathioprine was established to reduce the 
risk of adverse immunological reactions. Since the 
patient showed only partial clinical response, inflix-
imab was switched to adalimumab (40 mg biweekly), 
resulting in notable improvement. 18 months after 
the initiation of adalimumab treatment, asymptom-
atic, small, red to brown papules developed on the 
extremities. Multiple lesions were observed, initially 
on the legs, but the symptoms rapidly progressed to 
the arms and trunk (Figure 1). An acquired ichthyosis 
further complicated the disease course by extended, 
extremely xerotic, scaling skin lesions. Neither sys-
temic symptoms nor significant lymphadenopathy 
was observed. 
Figure 1. Clinical manifestation. (a) Multiple papules on the legs. (b) Scaling papules with a crusted necrotic center.
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The clinical picture suggested either ichthyosi-
form mycosis fungoides or a coincidence of LP and 
acquired ichthyosis. The histology of a typical papule 
showed perivascular and periadnexal lymphoid infil-
tration with massive hemorrhage in the dermis. The 
infiltration was dense, composed of small-to-medium-
sized lymphoid cells showing focal significant epider-
motropism (Figure 2). Most observed epidermal lym-
phocytes were CD3+, CD4+, and CD30+, while the 
dermal infiltration had higher CD4 and lower CD30 
expression (10-15%). Polymerase chain reaction (PCR) 
analysis of skin and peripheral blood samples did not 
show clonal rearrangement of T-cell receptor gamma 
(TcRgamma) genes. Normal phenotypes of lympho-
cyte subsets were detected by flow cytometry of pe-
ripheral blood. Ichthyosiform mycosis fungoides was 
excluded since histology of ichthyosiform skin lesions 
showed only hyperkeratosis with a reduced granular 
layer. While the cutaneous CD4+ epidermotropic in-
filtrate was suspicious of either mycosis fungoides or 
LP type B, the complexity of clinicopathological data 
confirmed the diagnosis of LP type B. The peripheral 
blood counts, serum biochemical tests, and urinalysis 
were within normal range, while the elevated serum 
anti-Saccharomyces cerevisiae antibodies (ASCA) 
of IgG and IgA subclasses indicated the activity of 
Crohn’s disease. Adalimumab and azathioprine were 
discontinued, and oral budesonide therapy was start-
ed in combination with topical corticosteroids and 
PUVA phototherapy. The skin lesions resolved with 
hyperpigmentation, and there was no relapse during 
the twelve-month follow-up.
Recent data suggest that LP occurs more com-
monly in immunocompromised patients, especially 
in those with solid organ or bone marrow trans-
plants (3). Though TNF-α inhibitors have dramati-
cally advanced the treatment of various diseases, the 
risk of lymphoma associated with their use remains 
controversial (5). Several cases of cutaneous lym-
phoproliferative disorders associated with TNF-α in-
hibitor treatment have been reported, including two 
patients with LP (6). One of the two patients with LP 
received infliximab for Crohn’s disease (7), while the 
other one had juvenile rheumatoid arthritis and re-
ceived adalimumab (8). Our case is the third report 
on LP developing under TNF-α inhibitor therapy and 
the first LP type B in a patient with Crohn’s disease 
treated with infliximab and later with adalimumab. 
A further interesting aspect of our case is that it also 
represents an example of the known association of 
acquired ichthyosis with inflammatory bowel disease 
(9). Multidisciplinary management was needed to 
provide optimal care and disease outcome for our 
patient. Since it is usually difficult to prove causality 
in most of such cases, it is important to collect similar 
clinical observations.   
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